Natus Medical Inc (NASDAQ:BABY) has been given an average recommendation of “Hold” by the six brokerages that are covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $44.00.

BABY has been the subject of a number of research reports. BidaskClub cut shares of Natus Medical from a “buy” rating to a “hold” rating in a report on Friday, September 7th. Zacks Investment Research cut shares of Natus Medical from a “hold” rating to a “sell” rating in a report on Friday, July 27th. Finally, ValuEngine cut shares of Natus Medical from a “hold” rating to a “sell” rating in a report on Wednesday, July 11th.

BABY opened at $32.01 on Wednesday. Natus Medical has a twelve month low of $28.00 and a twelve month high of $43.60. The company has a quick ratio of 2.19, a current ratio of 2.99 and a debt-to-equity ratio of 0.29. The firm has a market cap of $1.19 billion, a PE ratio of 22.08 and a beta of 0.59.

Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Wednesday, July 25th. The medical equipment provider reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.09. The business had revenue of $130.70 million during the quarter, compared to analysts’ expectations of $130.60 million. Natus Medical had a negative net margin of 4.16% and a positive return on equity of 11.18%. The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period last year, the company posted $0.34 earnings per share. As a group, research analysts anticipate that Natus Medical will post 1.55 earnings per share for the current fiscal year.

In other Natus Medical news, Director Robert A. Gunst sold 9,100 shares of the firm’s stock in a transaction on Friday, July 27th. The shares were sold at an average price of $34.11, for a total value of $310,401.00. Following the completion of the sale, the director now directly owns 54,982 shares in the company, valued at $1,875,436.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ken Ludlum sold 8,000 shares of the firm’s stock in a transaction on Thursday, August 2nd. The stock was sold at an average price of $36.89, for a total transaction of $295,120.00. Following the completion of the sale, the director now owns 98,957 shares of the company’s stock, valued at $3,650,523.73. The disclosure for this sale can be found here. Insiders sold 77,540 shares of company stock valued at $2,804,615 over the last 90 days. Corporate insiders own 5.50% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. Sei Investments Co. grew its holdings in shares of Natus Medical by 46.3% during the second quarter. Sei Investments Co. now owns 4,669 shares of the medical equipment provider’s stock valued at $161,000 after buying an additional 1,478 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Natus Medical by 2.2% during the second quarter. Legal & General Group Plc now owns 70,721 shares of the medical equipment provider’s stock valued at $2,460,000 after buying an additional 1,508 shares during the last quarter. Great West Life Assurance Co. Can grew its holdings in shares of Natus Medical by 4.3% during the first quarter. Great West Life Assurance Co. Can now owns 43,407 shares of the medical equipment provider’s stock valued at $1,459,000 after buying an additional 1,773 shares during the last quarter. MetLife Investment Advisors LLC grew its holdings in shares of Natus Medical by 14.2% during the second quarter. MetLife Investment Advisors LLC now owns 15,157 shares of the medical equipment provider’s stock valued at $523,000 after buying an additional 1,889 shares during the last quarter. Finally, US Bancorp DE grew its holdings in shares of Natus Medical by 81.2% during the first quarter. US Bancorp DE now owns 4,742 shares of the medical equipment provider’s stock valued at $159,000 after buying an additional 2,125 shares during the last quarter. Institutional investors and hedge funds own 96.88% of the company’s stock.

About Natus Medical

Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Further Reading: Calculate Your Return on Investment (ROI)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.